Clinical Trial Update: Proof-of-concept (PoC) Study of APD515 [Phase 2]

View source ↗

Summary

Acacia Pharma reports completion of a Phase 2 proof-of-concept study evaluating APD515 for xerostomia in patients with advanced cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Xerostomia

Drugs mentioned

• APD515

Snippet

Sponsor: Acacia Pharma Ltd | Conditions: Xerostomia in Advanced Cancer Patients | Phase 2 | Status: COMPLETED